Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | CAR-T updates in AML and ALL

Giovanni Martinelli • 7 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia CAR-T

Giovanni Martinelli, MD, University of Bologna, Bologna, Italy, highlights the key updates in CAR T-cell therapy for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Prof. Martinelli specifically discusses the dual anti-CD19/CD22 CAR T-cell product. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Giovanni Martinelli

1:20
Gilteritinib for FLT+ R/R AML
Giovanni Martinelli • 26 Oct 2019
1:01
Giovanni Martinelli: exciting CAR-T research
Giovanni Martinelli • 25 Oct 2019
1:36
Blinatumomab for R/R Ph+ AML
Giovanni Martinelli • 25 Oct 2019
1:12
How will we pave the way to transplant for high risk patients?
Giovanni Martinelli • 25 Oct 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals